

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2020

<https://marketpublishers.com/r/VD7E33882E3EN.html>

Date: May 2020

Pages: 96

Price: US\$ 2,000.00 (Single User License)

ID: VD7E33882E3EN

Abstracts

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H1 2020, provides an overview of the Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease) pipeline landscape.

Pathogenic strains of Enterococcus resistant to vancomycin are termed as Vancomycin-Resistant Enterococcus (VRE). Vancomycin-resistant enterococci have become a source of nosocomial infections. The symptoms of Vancomycin-resistant enterococci infection depend on where the infection lies. The bacteria usually infect the intestines, wounds and urinary tract. In case of wound infection, the area infected will be red and tender as well as swollen. In case of urinary tract infection, back pain and burning could occur when urination takes place. Other symptoms include nausea, fever, chills, severe headaches and diarrhea. Prevention requires effective hygienic practices.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Enterococcus faecium Infections – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive

pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant *Enterococcus faecium* Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 16 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively.

Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products

which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding

Vancomycin-Resistant *Enterococcus faecium* Infections (Infectious Disease)
pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Vancomycin-Resistant *Enterococcus faecium* Infections - Overview
- Vancomycin-Resistant *Enterococcus faecium* Infections - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Vancomycin-Resistant *Enterococcus faecium* Infections - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Vancomycin-Resistant *Enterococcus faecium* Infections - Companies Involved in Therapeutics Development
- Acurx Pharmaceuticals LLC
- AimMax Therapeutics Inc
- AnyGen Co Ltd
- Aphios Corp
- Arietis Corp
- Armata Pharmaceuticals Inc
- Curza Global LLC
- Daiichi Sankyo Co Ltd
- Helix BioMedix Inc
- Hsiri Therapeutics LLC
- Karveel Pharmaceuticals
- MGB Biopharma Ltd
- MicuRx Pharmaceuticals Inc
- Naicons Srl
- NovoBiotic Pharmaceuticals LLC
- Opal Biosciences Ltd
- Oragenics Inc
- Ovensa Inc
- QureTech Bio AB
- Rebiotix Inc
- Sealife PHARMA GMBH

Sentinella Pharmaceuticals Inc

Wockhardt Ltd

Vancomycin-Resistant *Enterococcus faecium* Infections - Drug Profiles

ACX-375C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AGM-290 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APY-281 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BDM-I - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

contezolid - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GmPcide-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HB-1345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HT-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IBN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Marinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGBBP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-108 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAI-603 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Novo-29 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OG-253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RBX-2660 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLP-0901 - Drug Profile
Product Description
Mechanism Of Action

R&D Progress

SLP-0904 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SLP-0905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Gram-Positive Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate CLPP for Vancomycin Resistant Enterococci Infections -
Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ftsz for Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug

Profile

Product Description

Mechanism Of Action

R&D Progress

SNP-021062 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides for Vancomycin Resistant Enterococci Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vancomycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WCK-4086 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects

Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products

Vancomycin-Resistant Enterococcus faecium Infections - Product Development

Milestones

Featured News & Press Releases

Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial For Novel Antibiotic MRX-I

Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics Project

Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress Towards Commercial Production of Lead Lantibiotic MU1140

May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent

Apr 23, 2012: MicuRx Completes Phase I Trial For MRX-I

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

[Contact Us](#)
[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Vancomycin-Resistant Enterococcus faecium Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Acurx Pharmaceuticals LLC, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AimMax Therapeutics Inc, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by AnyGen Co Ltd, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Aphios Corp, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Arietis Corp, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Curza Global LLC, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Daiichi Sankyo Co Ltd, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Helix BioMedix Inc, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Hsiri Therapeutics LLC, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Karveel Pharmaceuticals, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MGB Biopharma

Ltd, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by MicuRx
Pharmaceuticals Inc, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Naicons Srl, H1
2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by NovoBiotic
Pharmaceuticals LLC, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Opal Biosciences
Ltd, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Oragenics Inc, H1
2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Ovensa Inc, H1
2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by QureTech Bio AB,
H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Rebiotix Inc, H1
2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sealife PHARMA
GMBH, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Sentinella
Pharmaceuticals Inc, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline by Wockhardt Ltd, H1
2020

Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects, H1 2020
(Contd..1), H1 2020

Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products, H1
2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Vancomycin-Resistant *Enterococcus faecium* Infections, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Acurx Pharmaceuticals LLC

AimMax Therapeutics Inc

AnyGen Co Ltd

Aphios Corp

Arietis Corp

Armata Pharmaceuticals Inc

Curza Global LLC

Daiichi Sankyo Co Ltd

Helix BioMedix Inc

Hsiri Therapeutics LLC

Karveel Pharmaceuticals

MGB Biopharma Ltd

MicuRx Pharmaceuticals Inc

Naicons Srl

NovoBiotic Pharmaceuticals LLC

Opal Biosciences Ltd

Oragenics Inc

Ovensa Inc

QureTech Bio AB

Rebiotix Inc

Sealife PHARMA GMBH
Sentinella Pharmaceuticals Inc
Wockhardt Ltd

I would like to order

Product name: Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/VD7E33882E3EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VD7E33882E3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970